*Some Market data delayed by 15 mins.

AC Immune SA

Symbol: ACIU (NASDAQ)
3.99 ▲ (27.48%) 0.860

Company Description:
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Key Stats
  • Today's Open: $3.14
  • Today's High: $3.99
  • Today's Low: $3.065
  • Today's Volume: 1.07M
  • Yesterday Close: $3.13
  • Yesterday High: $3.22
  • Yesterday Low: $3.04
  • Yesterday Volume: 235.86K
  • Last Min Volume: 0
  • Last Min High: $3.99
  • Last Min Low: $3.977
  • Last Min VWAP: $0
Company Profile
  • Name: AC Immune SA
  • Website: https://www.acimmune.com
  • Listed Date: 2016-09-23
  • Location: ,
  • Market Status: Active
  • CIK Number: 0001651625
  • SIC Code:
  • SIC description:
  • Market Cap: $401.39M
  • Round Lot: 100
  • Outstanding Shares: 100.60M
  • Asset Type: CS
RECENT FILINGS FOR ACIU
Filing Date Filing Type Format
2025-10-03 144 View
2025-09-12 144 View
2025-09-04 6-K View
2025-08-05 6-K View
2025-07-24 144 View
2025-06-20 6-K View
2025-06-11 6-K View
2025-05-19 6-K View
2025-04-30 6-K View
2025-03-13 6-K View
2025-03-13 20-F View
2024-12-18 6-K View
2024-12-13 SC 13G/A View
2024-12-10 6-K View
2024-11-14 SC 13G/A View
2024-11-14 6-K View
2024-11-05 6-K View
2024-09-27 144 View
2024-09-19 6-K View
2024-09-18 144 View
Latest News on ACIU

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.